Traullé Catherine, Coiffier Bertrand B
Hospices Civils de Lyon, Hematology Department, CH Lyon-Sud, 69495 Pierre-Benite, France.
Future Oncol. 2005 Jun;1(3):297-306. doi: 10.1517/14796694.1.3.297.
Rituximab is the first monoclonal antibody to have been registered for the treatment of B-cell lymphomas. Randomized studies have demonstrated its activity in follicular lymphoma, mantle cell lymphoma, and diffuse large B-cell lymphoma in untreated or relapsing patients. Rituximab has transformed the outcome of these patients because of its high activity and low toxicity. A combination of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone, has the highest efficacy ever described with any chemotherapy in diffuse large B-cell lymphoma and follicular lymphoma.
利妥昔单抗是首个被注册用于治疗B细胞淋巴瘤的单克隆抗体。随机研究已证明其在未经治疗或复发患者的滤泡性淋巴瘤、套细胞淋巴瘤和弥漫性大B细胞淋巴瘤中具有活性。利妥昔单抗因其高活性和低毒性改变了这些患者的治疗结果。利妥昔单抗联合环磷酰胺、阿霉素、长春新碱和泼尼松，在弥漫性大B细胞淋巴瘤和滤泡性淋巴瘤中具有任何化疗方案所描述的最高疗效。
